WASHINGTON DC - The U.S. Department of Justice is accusing some of the most vocal opponents of federal marijuana rescheduling of trying to protect their own financial interests rather than public health. In a court filing submitted this week, DOJ attorneys argued that the National Drug and Alcohol Screening Association (NDASA) and MMJ International Holdings,
WASHINGTON DC — The federal government spent the opening day of historic marijuana rescheduling hearings Monday making arguments that would have been almost unimaginable just a few years ago: cannabis has accepted medical use, carries lower abuse potential than drugs in Schedule I and II, and presents a lower overdose risk than opioids and alcohol.
WASHINGTON DC - The Drug Enforcement Administration has invited only opponents of marijuana reform to participate in a June 29 hearing that could influence the future of federal cannabis policy, a decision that is drawing criticism from legalization advocates, consumer groups and state-licensed marijuana businesses that were excluded from the proceedings. The hearing, scheduled to
WASHINGTON DC - Tax revenues derived from the licensed retail sale of state-legal, adult-use cannabis products grew by more than 30 percent between 2020 and 2021, totaling over $3.7 billion last year – according to an analysis provided by the Marijuana Policy Project. MPP’s figures do not include revenues derived from the sales of medical cannabis products
